Table 2 Awaiting FDA approval
From: Potential new targets for drug development in severe asthma
| Â | Mechanism of Action | Biomarker | Outcomes | Significant Adverse Events | References |
|---|---|---|---|---|---|
Dupilumab (Completed phase III, under FDA review) | Anti-IL4R | ↑Peripheral eosinophils (≥300/uL) ↑Sputum eosinophils (≥3%) | Decreased exacerbations and symptoms Improved FEV1 Decreased glucocorticoid use Decreased FeNO |  |  |